

SOUTH SUDAN PENTAVALENT VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

| 1. Country: South Sudan | | | | | | | | | | | | | | | |
|---|---|---------------|---------------|--------------------------------------|--------------------|-------------------------|-----------------------|---------------|---------------|------------------------|--------|--------|-----------------------|---------------|---------------|
| 2. Grant Number: 1416-SDS-04c-X / 14-SDS-08a-Y | | | | | | | | | | | | | | | |
| 3. Date of Decision Letter: 6 October 2014 | | | | | | | | | | | | | | | |
| 4. Date of the Partnership Framework Agreement: 24 June 2013 | | | | | | | | | | | | | | | |
| 5. Programme Title: NVS, Pentavalent Routine | | | | | | | | | | | | | | | |
| 6. Vaccine type: Pentavalent | | | | | | | | | | | | | | | |
| 7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID | | | | | | | | | | | | | | | |
| 8. Programme Duration¹: 2014 - 2016 | | | | | | | | | | | | | | | |
| 9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement)²: | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th></th> <th>2014</th> <th>2015</th> <th>2016</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$2,429,000</td> <td>US\$2,478,500</td> <td>US\$2,337,000</td> <td>US\$7,244,500</td> </tr> </tbody> </table> | | 2014 | 2015 | 2016 | Total ² | Programme Budget (US\$) | US\$2,429,000 | US\$2,478,500 | US\$2,337,000 | US\$7,244,500 | | | | | |
| | 2014 | 2015 | 2016 | Total ² | | | | | | | | | | | |
| Programme Budget (US\$) | US\$2,429,000 | US\$2,478,500 | US\$2,337,000 | US\$7,244,500 | | | | | | | | | | | |
| 10. Vaccine Introduction Grant: Already disbursed in 2014 through WHO and UNICEF. | | | | | | | | | | | | | | | |
| 11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³ The Annual Amount for 2015 has been amended. | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with GAVI funds in each year</th> <th>2014</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of Pentavalent vaccines doses</td> <td>1,190,500</td> <td>1,223,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>1,167,000</td> <td>1,026,600</td> </tr> <tr> <td>Number of safety boxes</td> <td>12,975</td> <td>11,325</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$2,429,000</td> <td>US\$2,478,500</td> </tr> </tbody> </table> | Type of supplies to be purchased with GAVI funds in each year | 2014 | 2015 | Number of Pentavalent vaccines doses | 1,190,500 | 1,223,500 | Number of AD syringes | 1,167,000 | 1,026,600 | Number of safety boxes | 12,975 | 11,325 | Annual Amounts (US\$) | US\$2,429,000 | US\$2,478,500 |
| Type of supplies to be purchased with GAVI funds in each year | 2014 | 2015 | | | | | | | | | | | | | |
| Number of Pentavalent vaccines doses | 1,190,500 | 1,223,500 | | | | | | | | | | | | | |
| Number of AD syringes | 1,167,000 | 1,026,600 | | | | | | | | | | | | | |
| Number of safety boxes | 12,975 | 11,325 | | | | | | | | | | | | | |
| Annual Amounts (US\$) | US\$2,429,000 | US\$2,478,500 | | | | | | | | | | | | | |
| 12. Procurement agency: UNICEF. | | | | | | | | | | | | | | | |
| 13. Self-procurement: Not applicable. | | | | | | | | | | | | | | | |

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the amount that GAVI has approved.

14. Co-financing obligations: Reference code: 1416-SDS-04c-X-C According to the Co-Financing Policy, the Country will fall within the Intermediate Income group as of 1 January 2015. However the table below is based on the Country's current co-financing grouping as a low income country and the co-financing amounts for 2016 onwards will be revised following the High Level Review Panel in 2015.

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2014 | 2015 | 2016 |
|--|-------------|-------------|-------------|
| Number of vaccine doses | 133,500 | 134,500 | 158,000 |
| Value of vaccine doses (US\$) | US\$256,796 | | |
| Total Co-Financing Payments (US\$) (including freight) | US\$265,000 | US\$272,000 | US\$310,000 |

15. Operational support for campaigns: Not applicable

| | 2015 |
|---------------------|------|
| Grant amount (US\$) | |

16. Additional documents to be delivered for future disbursements:

| Reports, documents and other deliverables | Due dates |
|---|----------------------------------|
| Annual Progress Report or equivalent. | As agreed with Gavi Secretariat. |

17. Financial Clarifications: Not applicable.

18. Other conditions: Not applicable.

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

6 October 2014